Abb Vie Deutschland Gmbh & Co. Kg

Abbvie Inc.

Carolin Hoft

Helmut Mack

Margaretha Henrica Maria Bakker

Andreas Haupt

Wilfried Martin Braje

Karla Drescher

Ana Lucia Relo

Viktor Lakics

Hannes Koolman

Wilfried Hornberger

Sean Colm Turner

Marcel Van Gaalen

Xiaona Zhao

Ruxu Xu

The present invention relates to tricyclic quinoline and quinoxaline derivatives, to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HTreceptor, their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HTreceptor, and to a method for preventing or treating conditions and disorders which respond to the modulation of 5-HTreceptor.

Tricyclic quinoline and quinoxaline derivatives

The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description, which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3&#x3b2;, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3&#x3b2; activity using the compounds.

Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors

The present invention relates to novel heterocyclic compounds of formula I wherein the variables are as defined in the claims or the description,which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), compositions containing the compounds, their use for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a compound that modulates, preferably inhibits, the activity of glycogen synthase kinase 3&#x3b2;, and methods of treatment of medical disorders susceptible to treatment with a compound that modulates glycogen synthase kinase 3&#x3b2; activity using the compounds.

Growing community of inventors

Ludwigshafen, Germany

Carolin Hoft